Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Amgen Inc.

(AMGN)

Merrill Lynch analyst Jeffrey Casdin raised his 1995 EPS estimate on the Thousand Oaks, Calif., company to $3.75 from $3.70. He noted that

Epogen

erythropoietin is continuing its growth spurt and that

Neupogen

Read the full 387 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE